Industry Supports FDA Proposal to Create New Office of Patient Affairs
By Zachary Brennan -
Published 13 June 2017
Industry groups BIO and TransCelerate, as well as companies GlaxoSmithKline and Shire, have offered their support for the creation of a new office at the US Food and Drug Administration (FDA) focused on patient affairs.
Categories: News, US, FDA, Biologics and biotechnology, Business and Leadership, Drugs, Project management, Regulatory intelligence, Regulatory strategy
Tags: BIO, GSK, TransCelerate, Shire, Office of Patient Affairs, FDA patient engagement